Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Denis L Jardim

Showing results (1-10 of 25) with videos related to

Pageof 3
Sort By:
Lung Cancer Management|January 16, 2019
Recent results of immunotherapy and perspectives for advanced NSCLCDenis L Jardim, Debora de Melo Gagliato
Cell Cycle (Georgetown, Tex.)|March 14, 2014
MET in ovarian cancer: metastasis and resistance?Chad Tang, Denis L Jardim, David Hong
Integrative Cancer Therapies|September 20, 2018
Lessons From the Development of the Immune Checkpoint Inhibitors in OncologyDenis L Jardim, Débora de Melo Gagliato, Razelle Kurzrock
Cancer Cell|October 30, 2020
The Challenges of Tumor Mutational Burden as an Immunotherapy BiomarkerDenis L Jardim, Aaron Goodman, Debora de Melo Gagliato, et al.
Cancer Treatment Reviews|November 25, 2016
Factors associated with failure of oncology drugs in late-stage clinical development: A systematic reviewDenis L Jardim, Eric S Groves, Philip P Breitfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2017
Analysis of Drug Development Paradigms for Immune Checkpoint InhibitorsDenis L Jardim, Débora de Melo Gagliato, Francis J Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2013
Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugsDenis L Jardim, Kenneth R Hess, Patricia Lorusso, et al.
Oncoimmunology|February 1, 2020
Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compoundsDenis L Jardim, Débora De Melo Gagliato, Mina Nikanjam, et al.
Frontiers in Oncology|April 11, 2019
Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal CancerFranciele H Knebel, Fabiana Bettoni, Leonardo G da Fonseca, et al.
Journal of the National Cancer Institute|February 26, 2016
ResponseDenis L Jardim, Maria Schwaederle, J Jack Lee, et al.
Pageof 3

Showing results (1-10 of 25) with videos related to

Sort By:
Pageof 3
Lung Cancer Management|January 16, 2019
Recent results of immunotherapy and perspectives for advanced NSCLCDenis L Jardim, Debora de Melo Gagliato
Cell Cycle (Georgetown, Tex.)|March 14, 2014
MET in ovarian cancer: metastasis and resistance?Chad Tang, Denis L Jardim, David Hong
Integrative Cancer Therapies|September 20, 2018
Lessons From the Development of the Immune Checkpoint Inhibitors in OncologyDenis L Jardim, Débora de Melo Gagliato, Razelle Kurzrock
Cancer Cell|October 30, 2020
The Challenges of Tumor Mutational Burden as an Immunotherapy BiomarkerDenis L Jardim, Aaron Goodman, Debora de Melo Gagliato, et al.
Cancer Treatment Reviews|November 25, 2016
Factors associated with failure of oncology drugs in late-stage clinical development: A systematic reviewDenis L Jardim, Eric S Groves, Philip P Breitfeld, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 8, 2017
Analysis of Drug Development Paradigms for Immune Checkpoint InhibitorsDenis L Jardim, Débora de Melo Gagliato, Francis J Giles, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2013
Predictive value of phase I trials for safety in later trials and final approved dose: analysis of 61 approved cancer drugsDenis L Jardim, Kenneth R Hess, Patricia Lorusso, et al.
Oncoimmunology|February 1, 2020
Efficacy and safety of anticancer drug combinations: a meta-analysis of randomized trials with a focus on immunotherapeutics and gene-targeted compoundsDenis L Jardim, Débora De Melo Gagliato, Mina Nikanjam, et al.
Frontiers in Oncology|April 11, 2019
Circulating Tumor DNA Detection in the Management of Anti-EGFR Therapy for Advanced Colorectal CancerFranciele H Knebel, Fabiana Bettoni, Leonardo G da Fonseca, et al.
Journal of the National Cancer Institute|February 26, 2016
ResponseDenis L Jardim, Maria Schwaederle, J Jack Lee, et al.
Pageof 3